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Background: Transcatheter aortic valve implantation (TAVR) continues to develop as a
valuable alternative to surgical aortic valve replacement (SAVR) in an increasingly wide
spectrum of patients with severe symptomatic aortic stenosis (AS). AS frequently coexists
with coronary artery disease, and performing technically challenging percutaneous
coronary intervention (PCI) following TAVR will become more frequent with increased
use of TAVR.
Case Summary: We herein report the case of a 53-years-old man with complex medical
history including type 1 diabetes and dialysis-dependent renal failure and prior Evolut-R
TAVR for critical bicuspid aortic valve stenosis who underwent intravascular ultrasound
study (IVUS)-guided PCI to a critical distal left main stem (LMS) and proximal left anterior
descending (LAD) lesion after presenting with ventricular fibrillation (VF) secondary to an
acute coronary syndrome (ACS).
Discussion: Selective engagement of coronary ostia through the side cells of TAVR
prosthesis can be challenging, especially in an emergency setting. The particular
challenges associated with this case are described, as well as an up-to-date literature
search on strategies and equipment that can help in this situation.
Keywords: transcatheter aortic valve implantation, aortic stenosis, percutaneous intervention, case report,
coronary angiography
LEARNING POINTS
• The need for PCI following TAVR is not uncommon and is primarily related to coronary artery
disease progression.
• PCI post-TAVR is usually feasible and safe, although coronary intubation can be challenging due
to the superimposition of the metallic frame of the TAVR against the aortic root, particularly in
an emergency setting.
• PCI post-TAVR in bicuspid valve anatomy provides unique challenges to coronary access
resulting from the higher implant depth.
• The use of guide extension catheters can overcome the catheter intubation challenges.
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INTRODUCTION
Since the advent of transcatheter aortic valve replacement
(TAVR), its use has been rapidly expanding due to the growing
elderly population and concomitant age-related high prevalence
of aortic stenosis (AS). The expanding randomized controlled
trial evidence base now supports the appropriateness of TAVR,
in discussion with the heart team, in inoperable, high-risk,
intermediate-risk, and low-risk cases. This has led to an
exponential increase in procedural volume (1).
There is considerable overlap between the presence and
pathophysiology of atherosclerotic coronary artery disease
(CAD) and AS, with significant CAD observed in around half
of individuals presenting with severe AS (2), and as TAVR
inevitably expands toward themanagement of younger and lower
risk patients (3, 4), the likelihood of encountering potentially
significant CAD after TAVR requiring emergency or semi-
elective percutaneous coronary intervention (PCI) will increase.
This poses a new technical challenge for the coronary
interventionalist, whereby the design, material, and anatomic
orientation of various TAVRs may impact the feasibility and
safety of coronary angiography (CA) and PCI. The current
consensus on the optimal approach to investigation and
revascularization in these patients is limited (5). Therefore, we
hereby report a case of successful revascularization of complex
CAD of the left main stem (LMS) and left anterior descending
(LAD) with intravascular ultrasound study (IVUS)-guided PCI.
CASE DESCRIPTION
A 53-years-old man was referred to our institution following
cardiac arrest secondary to ventricular fibrillation (VF) while
receiving hemodialysis at a nearby hospital. He received
immediate cardiopulmonary resuscitation (CPR) and had return
of spontaneous circulation (ROSC) following two shocks
via transdermal defibrillator. His medical history included
type 1 diabetes with associated neuropathy, morbid obesity,
hemodialysis-dependent end-stage renal failure (ESRF), diffuse
coronary artery disease, and multiple sclerosis. Five months
earlier, following heart team discussion, he had undergone TAVR
with a 26-mm Medtronic Core Valve Evolut R (Medtronic,
Minneapolis, MN, USA) for severe symptomatic AS secondary
to a Sievers Type 0 bicuspid aortic valve. CA prior to TAVR,
9 months prior to admission, suggested mild LMS disease with
severe right coronary artery (RCA) disease, although image
quality was poor.
On admission, the patient was alert with a Glasgow Coma
Score of 15/15 and asymptomatic. Physical examination revealed
a pan-systolic murmur over the apex. Other physical findings
included pulmonary rales in the lower lung fields, mild distention
of the jugular veins, and mild lower extremity edema. A 12-
lead electrocardiogram showed sinus rhythm and biphasic T-
waves in the lateral leads. Venous blood gas analysis revealed
lactate, pH, and potassium within normal limits. Troponin T was
547 ng/L, rising to 836 ng/L on repeat assessment 10 h later, in
the context of end-stage chronic renal failure and a creatinine
of 440 µmol/L. Bedside transthoracic echocardiography (TTE)
showed long-standing akinesia of the inferolateral segments,
with mild left ventricular systolic impairment and inferolateral
hypokinesia. Chest X-ray revealed upper lobe blood diversion
and cardiomegaly only.
Timeline
Day 0 Patient with complex history (as detailed in case presentation) was
admitted following cardiac arrest secondary to VF while receiving
routine dialysis.
Day 0 Further episode of polymorphic ventricular tachycardia
Day 0 CA performed via left femoral artery. Difficulty engaging left and right
coronary cusps due to TAVR. Critical LMS, LAD, and intermediate
disease were described.
Day 1 Further VF arrest overnight. Proceeded to repeat CA and angioplasty to
LMS/LAD. Transferred to intensive care unit (ICU) for hemofiltration
considering ESRF and high contrast load.
Day 5 Decision for ICD, as residual CAD was felt to be a potential
arrhythmogenic substrate
Day 15 Secondary prevention ICD implanted
Day 21 Discharged home from our institution
Diagnostic Assessment, Intervention, and
Follow-Up
The decision wasmade to transfer the patient to the coronary care
unit (CCU) for observation, where he had a monitored episode
of non-sustained polymorphic ventricular tachycardia and
subsequently underwent CA. There were difficulties engaging
the LMS due to the TAVR cells, although the overall impression
was of severe LMS, LAD, and intermediate disease. The operator
was unable to comment on RCA disease, as they were unable
to selectively engage the RCA. The patient was commenced
on dual antiplatelet therapy and planned for multidisciplinary
team (MDT) discussion regarding the optimal approach to
management of his CAD. Overnight, in the CCU, the patient
experienced further VF with loss of cardiac output and required
resuscitation. There were no localizing ST segment changes
on 12-lead electrocardiography and a repeat Troponin T level
was 747 ng/L. He was therefore discussed the following day
with the surgical team in view of the clear pattern of diabetic
multivessel disease, which was felt to be best treated long term
with bypass; however, due to the high surgical risk, the decision
was made to pursue percutaneous angioplasty, accepting the risk
of incomplete revascularization.
The risks of the procedure were thoroughly discussed with the
patient who agreed. CA was undertaken via the right femoral
artery [ultrasound guided using a 7-French (7F) sheath]. A
second experienced PCI and TAVR operator then attempted to
selectively cannulate the LMS through the nitinol frame of the
CoreValve. Similar difficulties were encountered with a tendency
to engage superiorly and non-coaxially due to the high position
typical of a bicuspid implant and the orientation of the Evolut
commissures relative to the LMS origin. Eventually, selective
cannulation was achieved using a 7F JL4 guide catheter and 7F
guideliner over a 0.035-inch wire (Supplementary Video 1). CA
(Figure 1, Supplementary Video 2) confirmed a tapering distal
left main lesion, with critical proximal LAD disease and further
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severe ostial D1 lesion and diffuse diabetic disease throughout,
and severe proximal intermediate disease. The RCA was not
selectively intubated but was seen to be open proximally.
In order to clarify the appropriate PCI strategy, the LAD
and intermediate vessels were interrogated using IVUS. This
demonstrated a 2–2.5-mm intermediate vessel with extensive
calcification (360◦ calcium arc). Decision was made to treat
the culprit left main/LAD disease and to avoid a two-stent
bifurcation lesion involving the intermediate vessel in view of
the long-term risks of stent failure and probable non-viability
in the intermediate artery territory (long-standing inferolateral
akinesia on TTE). The LAD was predilated using a 2.5-mm
balloon with subsequent stent deployment with a 3.5 × 21mm
UltimasterTM sirolimus-eluting stent (Terumo Interventional
Systems) to the distal left main/LAD (Supplementary Figure 1,
Supplementary Video 3). Post-dilatation was performed using
a 3.5-mm non-compliant balloon to the LAD and 4.5/5-mm
balloon to the left main stem.
Kissing inflation was then undertaken to the LAD/first
diagonal branch using 2.5/3-mm balloons. An 8F Angioseal
was deployed for closure, and the patient was transferred to
the intensive care unit (ICU) overnight for filtration. Complete
revascularization of his severe diffuse diabetic three-vessel disease
was felt to be desirable but impractical without surgical conduits
and hence only the culprit lesion was treated. A subsequent MDT
confirmed the view that the substrate for ventricular arrhythmia
was likely to remain, and so he underwent implantable cardiac
defibrillator (ICD) implantation prior to his successful discharge.
DISCUSSION
TAVR has revolutionized themanagement of symptomatic severe
AS, and indications are expanding toward treating younger and
FIGURE 1 | Coronary angiography showing a tapering distal LMS lesion, with
critical proximal LAD disease. There is also a severe ostial D1 lesion, severe
proximal intermediate disease, and diffuse diabetic disease throughout.
lower risk patients (6). AS and CAD share common risk factors
and pathophysiology, and previous studies have shown a 30–
50% prevalence of CAD in patients with symptomatic severe
AS undergoing conventional surgical aortic valve replacement
(SAVR) (7, 8).
There is a paucity of data describing the incidence of coronary
events following TAVR, although given the progressive nature of
CAD, CA, and PCI will become increasingly necessary in patients
after TAVR (9). Therefore, acquisition of appropriate images of
the coronary arteries by selective CA is paramount to establish
an accurate diagnosis and management strategy. However, the
presence of a TAVR bioprosthesis could potentially complicate
or inhibit the selective catheterization of the coronary ostia.
Existing data, based on isolated cases and small series globally,
have assessed the safety and feasibility of CA and PCI following
TAVR. Chetcuti et al. (10) reported successful coronary access in
186/190 (97.9%) of their cases but successful PCI in only 103/113
cases (91.2%) following CoreValve TAVR.
FIGURE 2 | (A) The densely packed, horizontally aligned, narrow cells seen in
Lotus valves can result in difficulty with intubating the coronary ostia; (B,C) the
large cells and low density mesh of Sapien valves enable coronary
cannulation; (D) the large cell area of Portico and its annular positioning
facilitates easy coronary engagement although tall frame height can be
challenging; (E) the shorter stent design and larger cells of the upper section
of the Allegra stent frame might allow for easier coronary access; (F) Acurate
Neo valves display both favorable (short stent component) and unfavorable
(tall commissural post) features; (G) the relatively tall frame of Evolut R can
prove a challenge in coronary angiography, although the presence of a black
marker in principle facilitates optimal placement to simplify future coronary
access (11, 12). Modified from Todaro et al. (11) and Yudi et al. (5).
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FIGURE 3 | Coronary reaccess following TAVR. Modified from Todaro et al. (11) and Yudi et al. (5).
The different types of commonly used TAVR present various
challenges by virtue of their overall structure and cell size, as
illustrated in Figure 2 [modified from Todaro et al. (11) and
Yudi et al. (5)].
A large observational study by Zivelonghi et al. (13) compared
CA and PCI success rates in both balloon (Sapien 3; n =
41) and self-expandable (Evolut-R; n = 25) bioprosthesis and
concluded that catheterization of the coronary ostia after TAVR
was safe and feasible in most cases. However, in 4% of vessels,
selective angiography required positioning of a guidewire in the
vessel and only one artery could not be engaged due to the
high implantation of the Evolut-R, which was hypothesized to
be due to the leaflet base of the supra-annular valve landing
at the level of the origin of the coronary ostium (13). Tanaka
et al. (9) concluded that CA and PCI following the self-
expanding CoreValve TAVR are safe and feasible in most
cases [28 of 32 (87.5%) LMS angiography successful; 28 of
30 (93.3%) PCI successful], although described difficulty in
selective engagement of the RCA [16 of 32 (50%) successful].
The RE-ACCESS study by Barbanti et al. (14) enrolled 300
patients undergoing TAVR using all commercially available
devices (Figure 2). The primary endpoint, unsuccessful coronary
engagement following TAVR, was demonstrated in 23 of 300
patients (7.7%), which occurred almost exclusively in those
receiving Evolut-R devices (9).
With regard to balloon-expandable transcatheter valves, such
as the Sapien 3, the main difficulties reported across recent
case reports were due to the top of the valve frame partially or
completely obscuring the ostium, although this was overcome
with the use of either a balloon-assisted tracking or a guide
extension catheter (15). With regard to self-expandable valves,
such as the Evolut-R CoreValve, the main themes covered
by previous case reports and case series include difficulties
engaging the coronary ostia and the requirement for different
catheters and/or guide extensions to optimize guide support;
although despite these challenges, CA and PCI appear feasible,
even in complex disease, such as chronic total occlusions
(16). The role of post-TAVR computed tomography (CT)
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can be helpful in determining the anatomy and approach to
coronary access; however, it is limited in urgent situations,
such as acute coronary syndrome (ACS), and in patients
with renal insufficiency who are at increased risk of contrast
nephropathy (5).
As illustrated by Figure 3 [modified from Todaro et al. (11)
and Yudi et al. (5)], the challenges associated with coronary
reaccess following TAVR can be anatomical and procedural.
In order to tackle these particular challenges, Yudi et al. (5)
proposed a catheter selection algorithm depending on the type of
bioprosthesis (CoreValve, Medtronic, Minneapolis, Minnesota;
or Sapien, Edwards, Irvine, California), the type of procedure
(CA or PCI), and the position of the transcatheter valve
commissure with respect to the coronary ostium. This case
nicely demonstrated the utility of a 0.035-inch wire to cross
the desired diamond cell and provide a firm rail over which to
deliver a suitable guide extension and guide catheter as described
in their paper. We would agree that the narrow waist of the
CoreValve frame favors the use of the Judkins Left (JL) shape
over that of Extra back up (EBU) style for accessing the LMS
and hence smaller or short tipped JL catheters or even a Judkins
Right (JR) may successfully be employed. We would however
disagree with the systematic use of 6F guide catheters in more
complex anatomy.
Our case illustrates the limitations of this approach, as
typically a guide extension catheter is required to selectively
cannulate the coronary ostia in complex coronary anatomy.
A 6F guide extension then provides a working internal
lumen closer to 5F and so a complex intervention that
requires the use of multiple wires, intravascular imaging, or
certain calcium modification techniques may not always be
safely performed.
Our case also highlights the challenges unique to coronary
artery engagement in true bicuspid valve anatomy. Typically,
TAVR implants in bicuspid valves preferentially favor a higher
deployment that effectively means a greater chance of the sealing
skirt of a TAVR valve obstructing direct access to the coronaries.
For the CoreValve, this then mandates choosing a higher or
more lateral cell to successfully access the coronary ostia. This
increases the difficulty of delivery of catheters or equipment
due to lack of co-axial alignment. In this scenario, we would
strongly advocate the use of guide extensions to enable stents
and intravascular imaging catheters to be delivered safely to
the coronaries without the risk of entrapment or damage when
passing through the cells and around the sinus. Furthermore,
with hindsight, we would have considered the implantation of
a balloon expandable device, likely the Sapien 3, in the context
of high probability of future coronary intervention. Table 1
summarizes the factors to take into consideration when accessing
coronaries post-TAVR (5).
CONCLUSION
CAD remains one of the most frequent comorbidities among
TAVR candidates. Scarce data exist on the occurrence, impact,
and management of coronary events following TAVR. Although





• Frame/skirt height, cell size, commissure orientation
Baseline anatomy:
• Depth of TAVR implant, baseline aortic root anatomy,
coronary height, ascending aorta diameter
Complexity of coronary
intervention proposed
Consider need for intravascular imaging, Calcium
modification or two-stent strategies
Choice of guide LCA: Preference for smaller short-tipped JL shape
over EBU due to narrow aortic root constraints
RCA: JR4 or usual catheter choice
• French size: Guide extension use common and so
consider 6F, 7F, or 8F systems depending on
complexity of proposed intervention
Access Operator preference:
• Radial or ultrasound-guided femoral









• Use a 0.035-inch J wire to enter closest diamond
(ideally in front of coronary ostia). Railroad guide
extension, then guide catheter over wire.
• Stiff angled glide wire if difficulty persists
entering diamond
complex PCI is technically feasible following TAVR, this
requires an understanding of the anatomy of the valve
inserted, the relative implantation depth of the valve, the
orientation of the commissures, and the width of the aortic
root. In particular, the bicuspid anatomy provides unique
challenges that require careful planning. In addition to better
understanding the pathophysiology and establishing the most
appropriate treatment strategy in such cases, more data are
urgently needed regarding the coronary access, particularly
feasibility and failure rate, across different transcatheter
valve types.
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Supplementary Figure 1 | Coronary angiography showing 3.5 × 21 mm
UltimasterTM sirolimus-eluting stent in the distal LMS/LAD.
Supplementary Video 1 | Coronary angiography showing selective cannulation
using a 7F JL4 guide cather and 7F guideliner over a 0.035-inch wire.
Supplementary Video 2 | Coronary angiography showing a tapering distal LMS
lesion, with critical proximal LAD disease. There is also a severe ostial D1 lesion,
severe proximal intermediate disease, and diffuse diabetic disease throughout.
Supplementary Video 3 | Coronary angiography showing 3.5 × 21 mm
UltimasterTM sirolimus-eluting stent in the distal LMS/LAD.
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